TNSN98049A1 - Composition pharmaceutique a residence gastrique. - Google Patents

Composition pharmaceutique a residence gastrique.

Info

Publication number
TNSN98049A1
TNSN98049A1 TNTNSN98049A TNSN98049A TNSN98049A1 TN SN98049 A1 TNSN98049 A1 TN SN98049A1 TN TNSN98049 A TNTNSN98049 A TN TNSN98049A TN SN98049 A TNSN98049 A TN SN98049A TN SN98049 A1 TNSN98049 A1 TN SN98049A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical composition
gastric residence
carbon dioxide
benzamide
generating system
Prior art date
Application number
TNTNSN98049A
Other languages
English (en)
Inventor
Jerome Besse
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of TNSN98049A1 publication Critical patent/TNSN98049A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

CETTE COMPOSITION PHARMACEUTIQUE A RESIDENCE GASTRIQUE EST CARACTERISEE EN CE QU'ELLE COMPREND :(a) UN PRINCIPE ACTIF CONSISTANT EN UN BENZAMIDE OU UN SEL DE BENZAMIDE. (b) UN SYSTEME GENERATEUR DE DIOXYDE DE CARBONE, ET (c) UN MOYEN PERMETTANT LA RETENTION PARTIELLE DU DIOXYDE DE CARBONE GENERE PAR LEDIT SYSTEME GENERATEUR DE DIOXYDE DE CARBONE.
TNTNSN98049A 1997-04-18 1998-04-16 Composition pharmaceutique a residence gastrique. TNSN98049A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9704803A FR2762213B1 (fr) 1997-04-18 1997-04-18 Composition pharmaceutique a retention gastrique

Publications (1)

Publication Number Publication Date
TNSN98049A1 true TNSN98049A1 (fr) 2005-03-15

Family

ID=9506077

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98049A TNSN98049A1 (fr) 1997-04-18 1998-04-16 Composition pharmaceutique a residence gastrique.

Country Status (19)

Country Link
EP (1) EP0983065A1 (fr)
JP (1) JP2001523241A (fr)
KR (1) KR20010006353A (fr)
CN (1) CN1252720A (fr)
AR (1) AR015586A1 (fr)
AU (1) AU737634B2 (fr)
CA (1) CA2286081A1 (fr)
FR (1) FR2762213B1 (fr)
HU (1) HUP0002455A3 (fr)
IL (1) IL131995A0 (fr)
JO (1) JO2017B1 (fr)
MA (1) MA26482A1 (fr)
NO (1) NO995039L (fr)
NZ (1) NZ500288A (fr)
PE (1) PE68199A1 (fr)
PL (1) PL336273A1 (fr)
TN (1) TNSN98049A1 (fr)
WO (1) WO1998047506A1 (fr)
ZA (1) ZA983258B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
FR2790388B1 (fr) * 1999-03-04 2001-04-13 Synthelabo Compositions pharmaceutiques comprenant un benzamide et au moins un promoteur d'absorption
EP1245227A1 (fr) 2001-03-31 2002-10-02 Jagotec Ag Comprimé pharmaceutique flottant dans l'estomac destiné à la libération programmée du principe actif et procédé pour produire le matériel flottant compris dans le comprimé
WO2009157711A2 (fr) * 2008-06-24 2009-12-30 Park Eun-Seok Comprimé poreux gastro-rétentif et son procédé de préparation
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
EP2719376B1 (fr) 2012-10-12 2015-03-04 Omya International AG Formulation de médicament à rétention gastrique et systèmes d'administration et leur procédé de préparation à l'aide de carbonate de calcium fonctionnalisé
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2023214018A1 (fr) 2022-05-06 2023-11-09 Galenix Innovations Composition à libération prolongée gonflable à rétention gastrique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
FR2554718B1 (fr) * 1983-11-14 1986-04-04 Ethypharm Sa Nouvelles formes galeniques du sulpiride utilisables par voie orale
FR2556964A1 (fr) * 1983-12-23 1985-06-28 Ile De France Nouvelles formes galeniques du sulpiride utilisables par voie orale
JPS62178518A (ja) * 1986-01-30 1987-08-05 Toho Yakuhin Kogyo Kk 新規持続性スルピリド錠剤
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
CA2039742A1 (fr) * 1990-04-23 1991-10-24 Andrew B. Dennis Comprimes pour ingredients pharmaceutiques sujets a problemes : composition et mode de preparation

Also Published As

Publication number Publication date
EP0983065A1 (fr) 2000-03-08
AU737634B2 (en) 2001-08-23
WO1998047506A1 (fr) 1998-10-29
FR2762213B1 (fr) 1999-05-14
JP2001523241A (ja) 2001-11-20
ZA983258B (en) 1998-10-19
KR20010006353A (ko) 2001-01-26
HUP0002455A2 (hu) 2000-12-28
NZ500288A (en) 2001-03-30
JO2017B1 (en) 1999-05-15
NO995039D0 (no) 1999-10-15
AR015586A1 (es) 2001-05-16
AU7341698A (en) 1998-11-13
MA26482A1 (fr) 2004-12-20
CN1252720A (zh) 2000-05-10
PL336273A1 (en) 2000-06-19
IL131995A0 (en) 2001-03-19
FR2762213A1 (fr) 1998-10-23
HUP0002455A3 (en) 2001-01-29
NO995039L (no) 1999-12-17
PE68199A1 (es) 1999-07-15
CA2286081A1 (fr) 1998-10-29

Similar Documents

Publication Publication Date Title
BR9604803A (pt) Composição farmacêutica para administração oral
ATE293458T1 (de) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
TNSN98049A1 (fr) Composition pharmaceutique a residence gastrique.
HUP9803044A2 (hu) Ibuprofentartalmú készítmény
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
HUP9900560A2 (hu) PPAR-alfa és PPAR-gamma antagonisták alkalmazása X-szindróma kezelésében
UA41346C2 (uk) Фармацевтична композиція, яка містить флуоксетин або його сіль, таблетка на її основі, спосіб виробництва таблетки, яка диспергується
EA200000718A1 (ru) Композиции целекоксиба
RS49523B (sr) Vodeni farmaceutski rastvor
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
BG60101B2 (bg) Метод за получаване на 4-флуор-2-(((4-метокси-2- пиридинил)метил)тионил)-1н-бензимидазол
NO944214D0 (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
DE3875611D1 (de) Pharmazeutische zusammensetzungen.
IT1291278B1 (it) Preparazione farmaceutica a base di nimesulide per uso topico
ES2059633T3 (es) 2-terc.-butil-4-cloro-5-(4-terc.-butilbenciltio)-3(2h)-piridazinona para la lucha contra los moluscos.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
DK0669826T3 (da) (-)-Metrifonatholdigt lægemiddel
DE69220229D1 (de) Somatotropin zur erhoehung der reproduktiven leistung in rinder
ATE74505T1 (de) Schmerzpraeparat.
DE69834811D1 (de) Pelargonsäurevanillylamid enthaltendes tränengas
KR890007737A (ko) 진토작용을 하는 약제
RU95119067A (ru) Способ стимуляции половой функции крупного рогатого скота
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість